GlassScriptPhysician profile
Atiya Chachar
NPI 1174974398
$2,049.15
in general payments reported to CMS, 2019-2025
20 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $577 · 2024: $529 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.73 |
| Education | $171.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $276.44 | 2022-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $251.94 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $225.09 | 2023-2025 | Farxiga, Lokelma |
| Amgen INC. | $212.57 | 2022-2025 | Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $173.11 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $168.36 | 2022-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $162.74 | 2022-2025 | Lupkynis |
| Travere Therapeutics, INC. | $114.90 | 2023-2025 | Filspari, Thiola |
| Ardelyx, INC. | $81.97 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $78.18 | 2022-2025 | Velphoro, Korsuva, Velphoro |
| Calliditas Therapeutics US INC. | $47.55 | 2025 | Tarpeyo |
| Vifor Pharma, INC. | $43.98 | 2023-2024 | Veltassa, Korsuva |
| Lilly USA, LLC | $38.92 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Horizon Therapeutics Plc | $38.86 | 2022-2023 | Krystexxa |
| Vantive US Healthcare LLC | $30.88 | 2025 | Renal - Crrt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23.69 | 2022 | |
| One Lambda, INC. | $21.99 | 2025 | |
| Shield Therapeutics INC | $20.32 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.37 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $18.29 | 2023 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atiya Chachar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.